載入中
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
前收盤價
US$10.72
−US$0.28 · -2.55%
盤中時間採用ET。市場資料可能有所延遲。
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
日內區間
目前US$10.72
52週區間
目前US$10.72
盤中時間採用ET。市場資料可能有所延遲。
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
日內區間
目前US$10.72
52週區間
目前US$10.72
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 18.17萬 USD | 21.54萬 USD | 20.46萬 USD | 12.17萬 USD | 7.8萬 USD |
| 毛利 | −18.17萬 USD | −21.54萬 USD | −20.46萬 USD | −12.17萬 USD | −7.8萬 USD |
| 研究與開發 | 575.75萬 USD | 633.61萬 USD | 1549萬 USD | 2311.51萬 USD | 1396.64萬 USD |
| 銷售、一般及管理費用 | 654.81萬 USD | 409.87萬 USD | 743.11萬 USD | 771.24萬 USD | 456.2萬 USD |
| 營業費用 | 1230.56萬 USD | 1043.48萬 USD | 2271.65萬 USD | 3082.75萬 USD | 1852.83萬 USD |
| 利息收入 | 18.02萬 USD | 17.26萬 USD | 46.33萬 USD | 25.33萬 USD | — |
| 利息支出 | — | — | — | 25.33萬 USD | 243.16萬 USD |
| 折舊和攤銷 | 18.17萬 USD | 21.54萬 USD | 20.46萬 USD | 12.17萬 USD | 7.8萬 USD |
| 營業利益 | −1248.73萬 USD | −1065.02萬 USD | −2292.11萬 USD | −3094.93萬 USD | −1860.63萬 USD |
| 淨利 | −1249.43萬 USD | −1078.48萬 USD | −2245.79萬 USD | −2799.12萬 USD | −3021.28萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$35.00
上漲空間 226.49%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年1月28日 | 1:10 | — | — |
已生效 2025年1月28日
1:10
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
